复荣通脉胶囊联合西洛他唑片治疗糖尿病下肢血管病变临床研究

Clinical Observation for the Treatment of Diabetic Peripheral Vascular Lesions by Furong Tongmai Capsule Combined with Cilostazol

目的观察复荣通脉胶囊联合西洛他唑治疗糖尿病下肢血管病变的临床疗效。方法将60例糖尿病下肢血管病变患者随机分为治疗组和对照组各30例,2组均予常规治疗,在此基础上,治疗组给予复荣通脉胶囊联合西洛他唑片口服,对照组仅予西洛他唑片口服,观察2组患者治疗前后临床症状、足背温度、踝肱指数(ABI)及血脂的变化。结果治疗组总有效率为76.7%(23/30),对照组为50.0%(15/30),治疗组疗效明显优于对照组(P<0.05);与治疗前比较,2组患者治疗后间歇性跛行、静息痛及足部冷凉均得到一定程度改善,中医症候积分明显降低,且治疗组优于对照组(P<0.05,P<0.01);2组患者治疗后ABI、足背温度与治疗前比较差异均有统计学意义(P<0.01),且治疗组改善优于对照组(P<0.01);2组患者治疗后总胆固醇、三酰甘油、纤维蛋白原与治疗前比较差异均有统计学意义(P<0.01),且均优于对照组(P<0.05,P<0.01)。结论复荣通脉胶囊联合西洛他唑片治疗糖尿病下肢血管病变的疗效优于单用西洛他唑片。

Objective To observed the clinical efficacy of the treatment of diabetic peripheral vascular lesions byFurong Tongmai Capsule combined with cilostazol. Methods Sixty patients with diabetic peripheral vascular lesionswere randomly divided into the treatment group and the control group, 30 cases in each group. Both of the two groupsreceived conventional treatment. Treatment group was given compound Furong Tongmai Capsule oral combined withcilostazol, while control group used cilostazol orally only. Clinical symptoms, the changes of skin temperature, ABIand blood lipid in the two groups were observed. Results The total effective rate was 76.7% (23/30) in the treatmentgroup and 50.0% (15/30) in the control group, and the curative effect of treatment group was obviously better thanthat of control group (P<0.05); After treatment, intermittent claudication, rest pain, and the feet coldness wereimproved to a certain extent, and TCM symptom scores decreased significantly, with better efficacy in treatmentgroup (P<0.05); After treatment, ABI, foot back temperature showed statistical significance in the two groups, withbetter efficacy in treatment group (P<0.01); After treatment, TC, TG, FIB showed statistical significance in the twogroups, with better efficacy in treatment group (P<0.05, P<0.01). Conclusion The efficacy of Furong TongmaiCapsule combined with cilostazol for diabetic peripheral vascular lesions is better than cilostazol only.